Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 4,175 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control comparison Clear all

Conditions: Depressive Symptoms, Mild Traumatic Brain Injury
Interventions: CNRM DTx, Psychoeducation Comparison; Device · Other
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Preeclampsia Severe, Preeclampsia Postpartum
Interventions: Magnesium Sulfate; Drug
Lead sponsor: Alexander Harrison; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Total Hip Replacement (Non-inflammatory)
Interventions: Novation Ceramic; Device
Lead sponsor: Exactech; Industry
Eligibility: 21 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2021
U.S. locations: 5
States / cities: Fort Lauderdale, Florida • Cumming, Georgia • Worcester, Massachusetts + 2 more

Conditions: Dry Eye Disease
Interventions: OK-101, Placebo; Drug
Lead sponsor: Okyo Pharma Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 6
States / cities: Newport Beach, California • Colorado Springs, Colorado • Louisville, Kentucky + 3 more

Conditions: Smoking
Interventions: Saliva sample, Urine Sample, Toe nail clippings, Breath carbon monoxide test; Other
Lead sponsor: University of Florida; Other
Eligibility: 6 Years to 17 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Gainesville, Florida • Oklahoma City, Oklahoma

Conditions: Intermetatarsal Neuroma
Interventions: Cryoablation, Lidocaine, Saline; Device · Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Systemic Lupus Erythematosus, Sjogren's Syndrome
Interventions: BioCLIA Ro60; Device
Lead sponsor: HOB Biotech Group; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Irvine, California

Conditions: Cancer
Interventions: Exercise and relaxation intervention; Behavioral
Lead sponsor: The Miriam Hospital; Other
Eligibility: 18 Years to 39 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Treatment Resistant Depression
Interventions: VLS-01-203 BU, VLS-01-BU Placebo; Drug
Lead sponsor: atai Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 34
States / cities: Tucson, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 30 more

Conditions: Contraception
Interventions: Ulipristal Acetate, Combined Oral Contraceptive Pill; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: New York, New York

Conditions: Pulmonary Hypertension
Interventions: Oral treprostinil (UT-15C) sustained release tablets, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 39
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 31 more

Conditions: Heart Failure and Reduced Ejection Fraction
Interventions: LCZ696 (sacubitril/valsartan), Enalapril, Placebo of Enalapril, Placebo of LCZ696; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 81
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 69 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Aclidinium bromide, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 110
States / cities: Birmingham, Alabama • Muscle Shoals, Alabama • Pell City, Alabama + 94 more

Conditions: Hyperglycemia, Hyperlipidemia
Interventions: Olanzapine, Ziprasidone; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hypertension
Interventions: Motivational interviewing (MINT-TLC); Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 373 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Severe Spasticity
Interventions: intrathecal baclofen; Drug
Lead sponsor: MedtronicNeuro; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 9
States / cities: Irvine, California • Washington D.C., District of Columbia • Doral, Florida + 6 more

Conditions: HIV Infections, Sexually Transmitted Diseases
Interventions: Many Men, Many Voices (3MV); Behavioral
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 341 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Seasonal Affective Disorder
Interventions: Extended-release bupropion hydrochloride; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 43
States / cities: Anchorage, Alaska • Hamden, Connecticut • Boise, Idaho + 37 more

Conditions: Stargardt's Macular Dystrophy
Interventions: avacincaptad pegol, Sham; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 17
States / cities: Phoenix, Arizona • Los Angeles, California • Gainesville, Florida + 14 more

Conditions: Preterm Premature Rupture of the Membranes, Physical Activity
Interventions: Moderate Activity; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: San Diego, California

Conditions: Diabetes Mellitus, Type 2
Interventions: TAK-875, TAK-875 Placebo, Glimepiride; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 38
States / cities: Muscle Shoals, Alabama • Phoenix, Arizona • Fresno, California + 35 more

Conditions: Chronic Kidney Disease, Autosomal Dominant Polycystic Kidney Disease
Interventions: Tolvaptan (OPC-41061), Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 82
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 73 more

Conditions: Dry Eye Disease
Interventions: Varenicline solution, Placebo nasal spray (OC-01 Vehicle Nasal Spray); Drug
Lead sponsor: Stephenson Eye Associates; Other
Eligibility: 22 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Venice, Florida

Conditions: Spine Surgery, Excessive Repair, Spinal Cord Injuries, Complication of Surgical Procedure
Interventions: Spinal Sealant, Standard Methods of Closing of the Dura; Device · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Digital Therapeutic for Depression After Head Injury in Current and Former US Military Personnel

Biomarkers in Management of Post Partum Preeclampsia

Post Approval Study: NOVATION Ceramic Articulation Hip System

The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease

Comparison of Smoking and Vaping in Families

Compare Ultrasound Assisted Cold Therapy and Lidocaine Injection to Treat Morton's Neuroma

Clinical Performance of BioCLIA Ro60

Exercise and Relaxation Intervention for Young Adult Cancer Survivors

A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation

FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)

Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction

Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)

Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone

Faith-based Approaches in the Treatment of Hypertension (FAITH)

SISTERS: Spasticity In Stroke Study - Randomized Study

Evaluation of Many Men, Many Voices, An STD/HIV Prevention Intervention for Black MSM

Prevention of Seasonal Affective Disorder

Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)

A Comparison of Bed Rest Versus Moderate Activity in Preterm Premature Rupture of Membranes (PPROM)

Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes

Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease

Evaluation of Tear Film Quality and Stability in Subjects With Dry Eye Disease Using OC-01 (Varenicline Solution) Nasal Spray 0.03 mg as Compared to Vehicle Control Nasal Spray

Use of Spinal Sealant System During Spinal Surgery